Skip to main content
SpringerLink
Log in

Lipoprotein (a): A risk factor for peripheral vascular disease

  • Original Articles
  • Published:
Annals of Vascular Surgery

Abstract

Lipoprotein (a) [Lp(a)] is a serum protein that has been reported to be predictive of complications from coronary and cerebrovascular atherosclerotic disease. This study was designed to compare plasma levels of Lp(a) in 100 white male patients with and without peripheral vascular disease (PVD) and to determine the role of Lp(a) as a risk factor for PVD independent of known risk factors such as cigarette smoking (CIG), diabetes mellitus (DM), and coronary artery disease (CAD). Patients with PVD (mean age =67.6 years, n=50) had a statistically significant (p=0.04) elevation of Lp(a) (29.8±3.9 mg/dl) as compared to patients without PVD (20.0±2.9 mg/dl (mean age =68.3 years, n=50). Further analysis revealed that patients with PVD had a significantly higher incidence of CIG (86% vs. 68%,p=0.03), DM (34% vs. 14%,p=0.02), and CAD (52% vs. 30%,p=0.02) than those without PVD. However, there was no statistically significant difference in Lp(a) levels in patients with CIG or CAD compared to those without. Patients with DM had significantly (p=0.04) lower levels of Lp(a) (17.8±3.5 mg/dl) than those without DM (27.1±3.0 mg/dl). Stepwise regression analysis of these various risk factors for PVD revealed that Lp(a) was the strongest significant individual predictor for the presence of PVD (R 2=0.07) as compared to DM (R 2=0.05) and CIG (R 2=0.04). We conclude that there is a significant correlation of Lp(a) levels and the incidence of PVD, which is independent of other major risk factors for PVD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Berg K. A new serum type system in man — the Lp system. Acta Pathol Microbiol Scand 1963;59:369–382.

    PubMed  Google Scholar 

  2. Scanu AM. Lipoprotein (a): A potential-bridge between the fields of atherosclerosis and thrombosis. Arch Pathol Lab Med 1988;112:1045–1047.

    PubMed  Google Scholar 

  3. Albers JJ, Cabana VG, Warnick GR, et al. Lp(a) lipoprotein: Relationship to sinking pre-β1-lipoprotein, hyperlipoproteinemia and apo-lipoprotein B. Metabolism 1975;24:1047–1054.

    PubMed  Google Scholar 

  4. Dahlen GH. Lipoprotein (a) in relation to atherosclerotic diseases. In Naito HK, Widhalm K, eds. Recent Aspects of Diagnosis and Treatment of Lipoprotein Disorders: Impact on Prevention of Atherosclerotic Diseases. New York: Alan R. Liss, 1988, pp 27–36.

    Google Scholar 

  5. Utermann G, Menzel HJ, Kraft HG, et al. Lp(a) glycoprotein phenotypes: Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. J Clin Invest 1987;80:458–465.

    PubMed  Google Scholar 

  6. Carlson LA, Hamsten A, Asplund A. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidemic subjects treated with nicotinic acid. J Intern Med 1989;226:271–276.

    PubMed  Google Scholar 

  7. Thompson PD, Cullinane EM, Sady SP, et al. Contrasting effects of testosterone and stanozolol on serum lipoprotein levels. JAMA 1989;261:1165–1168.

    PubMed  Google Scholar 

  8. Maede S, Abe A, Seishima M, et al. Transient changes of serum lipoprotein(a) as an acute phase protein. Atherosclerosis 1989;78:145–150.

    PubMed  Google Scholar 

  9. Dahlen G, Ericson C. A new lipoprotein pattern in patients with angina pectoris. Scand J Clin Lab Invest 1971;118(Suppl):54.

    Google Scholar 

  10. Armstrong VW, Cremer P, Eberle E, et al. The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis. Atherosclerosis 1986;62:249–257.

    PubMed  Google Scholar 

  11. Dahlen GH, Guyton JR, Attar M, et al. Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation 1986;74:758–765.

    PubMed  Google Scholar 

  12. Kostner GM, Avogaro P, Cassolato G, et al. Lipoprotein Lp(a) and the risk for myocardial infarction. Atherosclerosis 1981;38:51–61.

    PubMed  Google Scholar 

  13. Koltringer P, Jurgens B. A dominant role of lipoprotein(a) in the investigation and evaluation of parameters indicating the development of cervical atherosclerosis. Atherosclerosis 1985;58:187–198.

    PubMed  Google Scholar 

  14. Murai A, Miyahara T, Fujimoto N, et al. Lp(a) lipoprotein as a risk factor for coronary heart disease and cerebral infarction. Atherosclerosis 1986;59:199–204.

    PubMed  Google Scholar 

  15. Guyton JR, Dahlen GH, Patsch W, et al. Relationship of plasma Lp(a) levels to race and to apolipoprotein B. Arteriosclerosis 1985;5:265–272.

    PubMed  Google Scholar 

  16. Dahlen G, Frick MH, Berg K, et al. Further studies of Lp(a) lipoprotein/pre-β1-lipoprotein in patients with coronary heart disease. Clin Genet 1975;8:183–189.

    PubMed  Google Scholar 

  17. Dahlen G, Garsten P, Erikson H, et al. Insulin response to an oral glucose load in relation to Lp(a)/pre-β1-lipoprotein levels in non-diabetic patients with peripheral vascular disease and in controls. Acta Chir Scand 1979;145:447–454.

    PubMed  Google Scholar 

  18. Rhoads GG, Dahlen G, Berg K, et al. Lp(a) lipoprotein as a risk factor for myocardial infarction. JAMA 1986;256:2540–2544.

    PubMed  Google Scholar 

  19. Fuchs JCA. Atherogenesis and the medical management of atherosclerosis. In Rutherford RB, ed. Vascular Surgery, 3rd ed. Philadelphia: WB Saunders, 1989, pp 194–206.

    Google Scholar 

  20. Molgaard J, Klausen C, Lassvik C, et al. Significant association between low-molecular-weight apolipoprotein (a) isoforms and intermittent claudication. Arteriosclerosis Thromb 1992;12:895–901.

    Google Scholar 

  21. Mertz DP, Burvenich K. Unterschiedliche werte von lipoprotein Lp(a) bei erwachsenen diabetikern in abhangigkeit von der therapieform. Klin Wochenschr 1985;63:648–650.

    PubMed  Google Scholar 

  22. Bruckert E, Davidoff P, Grimaldi A, et al. Increased serum levels of lipoprotein(a) in diabetes mellitus and their reduction with glycemic control. JAMA 1990;263:35–36.

    Google Scholar 

  23. Joven J, Vilella E. Serum levels of lipoprotein(a) in patients with well-controlled non-insulin-dependent diabetes mellitus. JAMA 1991;265:1113–1114.

    PubMed  Google Scholar 

  24. Rath M, Niendorf A, Reblin T, et al. Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis 1989;9:579–592.

    PubMed  Google Scholar 

  25. Walton KW, Hitchens J, Magnani HN, et al. A study of methods of identification and estimation of Lp(a) lipoprotein and of its significance in health, hyperlipidemia and atherosclerosis. Atherosclerosis 1974;20:323–346.

    PubMed  Google Scholar 

  26. Cushing GL, Gaubatz JW, Nava ML, et al. Quantitation and localization of apolipoproteins [a] and B in coronary artery bypass grafts resected at reoperation. Arteriosclerosis 1989;9:593–603.

    PubMed  Google Scholar 

  27. Houlson R, Friedl W. Biochemistry and clinical significance of lipoprotein(a). Ann Clin Biochem 1988;25:499–503.

    PubMed  Google Scholar 

  28. Utermann G. The mysteries of lipoprotein(a). Science 1989;246:904–910.

    PubMed  Google Scholar 

  29. Karadi I, Kostner GM, Gries A, et al. Lipoprotein (a) and plasminogen are immunochemically related. Biochem Biophys Acta 1988;960:91–97.

    PubMed  Google Scholar 

  30. Edelberg JM, Gonzalez-Gronow M, Pizzo SV. Lipoprotein(a) inhibition of plasminogen activation by tissue-type plasminogen activator. Thromb Res 1990;57:155–162.

    PubMed  Google Scholar 

  31. Hajjar KA, Gavish D, Breslow JL, et al. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature 1989;339:303–305.

    PubMed  Google Scholar 

  32. Miles LA, Fless GM, Levin EG, et al. A potential basis for the thrombotic risks associated with lipoprotein(a). Nature 1989;339:301–303.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Vascular Surgery, Department of Surgery, Yale University School of Medicine, 333 Cedar St., PO Box 3333, 06510, New Haven, CT

    Mark D. Widmann MD & Bauer E. Sumpio MD, PhD

Authors
  1. Mark D. Widmann MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bauer E. Sumpio MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Supported by grants NIH NRSA F32HL0824501A1 to M.D.W. and NIH R29HL40305, RO1HL47345, and VA Merit Grant to B.E.S.

About this article

Cite this article

Widmann, M.D., Sumpio, B.E. Lipoprotein (a): A risk factor for peripheral vascular disease. Annals of Vascular Surgery 7, 446–451 (1993). https://doi.org/10.1007/BF02002128

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02002128

Keywords

Search

Navigation